TEPEZZA
TEPEZZA, also known by its generic name teprotumumab-trb, is a medication used to treat thyroid eye disease (TED) [1]. It is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor [1].
How does TEPEZZA work for thyroid eye disease?
TEPEZZA works by targeting the underlying cause of TED, which is an autoimmune process that affects the tissues around the eye [1]. The disease involves inflammation and swelling of the muscles and fat behind the eye, leading to symptoms such as bulging eyes (proptosis), double vision, and pain [2]. TEPEZZA binds to the IGF-1 receptor, which is found on cells in the orbital tissue. By inhibiting this receptor, it reduces inflammation and swelling, helping to alleviate the symptoms of TED [1][3].
What symptoms does TEPEZZA treat?
TEPEZZA is indicated for the treatment of adult patients with active Graves' eye disease, also known as thyroid eye disease [1]. It helps to reduce eye bulging, double vision, and other symptoms associated with the condition [2]. Clinical trials have shown significant improvements in proptosis and diplopia in patients treated with TEPEZZA [3].
What are the potential side effects of TEPEZZA?
Common side effects of TEPEZZA include muscle spasms, nausea, diarrhea, hair loss, decreased appetite, and dry skin [1]. Infrequently, it can cause infusion reactions, hyperglycemia, and hearing impairment, including hearing loss or ringing in the ears [1][4]. Patients with pre-existing hearing issues should discuss this risk with their doctor before starting treatment [4].
How is TEPEZZA administered?
TEPEZZA is administered as an intravenous (IV) infusion every three weeks for a total of eight infusions [1]. The infusion is typically given in a healthcare setting by a trained professional [3].
What is the patent status and exclusivity for TEPEZZA?
The original patent for TEPEZZA was filed by Horizon Therapeutics, now part of Amgen [5]. DrugPatentWatch.com tracks patents and exclusivity periods for drugs like TEPEZZA, providing insights into when generic versions might become available [6]. Information regarding specific patent expiry dates and any ongoing litigation can be found through specialized patent databases [6].
When might generic versions of TEPEZZA become available?
The availability of generic versions of TEPEZZA depends on patent expiry and any potential patent challenges [6]. Until exclusivity periods expire or are successfully challenged, only the branded version is available [6].
How does TEPEZZA compare to other treatments for thyroid eye disease?
Historically, treatments for TED have included high-dose corticosteroids, orbital radiation, and surgery [2]. Corticosteroids can help manage inflammation but may not address the underlying disease progression and can have significant side effects. Surgery is typically reserved for later stages of the disease to address disfigurement and vision problems [2]. TEPEZZA represents a novel therapeutic approach that targets the disease pathophysiology directly, offering a medical treatment option for active TED [1][3].